Literature DB >> 22921272

A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer.

Polat Dursun1, Serkan Erkanli, Ahmet Bariş Güzel, Murat Gultekin, Nefise Cagla Tarhan, Ozden Altundag, Fuat Demirkiran, Tugan Beşe, Yusuf Yildirim, Gurkan Bozdag, Hakan Yarali, Tayyup Simsek, Bulent Ozcelik, Firat Ortaç, Salih Taskin, Tevfik Guvenal, Nejat Ozgul, Ali Haberal, M Ali Vardar, Murat Dede, Mufit Yenen, Aytekin Altintas, Macit Arvas, Ali Ayhan.   

Abstract

OBJECTIVE: To analyze the results of fertility-sparing treatment of early-stage endometrial cancer (EC) in patients treated at Turkish gynecologic oncology centers, and to present a review of the literature.
METHODS: Thirteen healthcare centers in Turkey were contacted to determine if they were eligible to participate in the study. Centers that were eligible and agreed to participate were sent a database form to record the demographic characteristics, clinicopathologic findings, and follow-up results for their EC patients.
RESULTS: Eleven Turkish healthcare centers provided data on 43 EC patients. Mean duration of treatment was 5 months and mean follow-up was 49 months. In total, 35 (81.4%) patients were tumor free following primary progesterone therapy. Mean time from the end of progesterone therapy to pregnancy was 10.6 ± 4.3 months (range, 3-18 months). Two patients had tumor recurrence during follow-up. The pregnancy rate among the 31 women who actively sought pregnancy was 41.9% (n=13).
CONCLUSION: Conservative management of early-stage EC in women of reproductive age using oral progestins was effective and did not compromise oncological outcome. Pregnancy in the study patients was achieved spontaneously and artificially.
Copyright © 2012 International Federation of Gynecology and Obstetrics. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921272     DOI: 10.1016/j.ijgo.2012.06.010

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  4 in total

1.  The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer.

Authors:  Akihisa Fujimoto; Mari Ichinose; Miyuki Harada; Tetsuya Hirata; Yutaka Osuga; Tomoyuki Fujii
Journal:  J Assist Reprod Genet       Date:  2014-08-10       Impact factor: 3.412

Review 2.  Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.

Authors:  Qing Zhang; Gonghua Qi; Margaux J Kanis; Ruifen Dong; Baoxia Cui; Xingsheng Yang; Beihua Kong
Journal:  Oncotarget       Date:  2017-05-03

3.  A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.

Authors:  Zhibo Zhang; Huifang Huang; Fengzhi Feng; Jinhui Wang; Ninghai Cheng
Journal:  J Gynecol Oncol       Date:  2019-02-26       Impact factor: 4.401

Review 4.  Fertility issue in early stage endometrial cancer patients.

Authors:  Hasan Onur Topçu; Cihan Kaya; Engin Oral
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.